Intravenous Ustekinumab Reinduction Is Effective in Prior Biologic Failure Crohn’s Disease Patients Already on Every-4-Week Dosing
- 1 July 2021
- journal article
- letter
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 19 (7) , 1497-1498.e1
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Open: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY ConsortiumAmerican Journal of Gastroenterology, 2018
- Systematic review and network meta‐analysis: first‐ and second‐line biologic therapies for moderate‐severe Crohn's diseaseAlimentary Pharmacology & Therapeutics, 2018
- Association Between Ustekinumab Trough Concentrations and Clinical, Biomarker, and Endoscopic Outcomes in Patients With Crohn’s DiseaseClinical Gastroenterology and Hepatology, 2017
- Ustekinumab as Induction and Maintenance Therapy for Crohn’s DiseaseNew England Journal of Medicine, 2016
- Physician Global Assessments or Blood tests do not Predict Mucosal Disease Activity in Ulcerative ColitisCanadian Journal of Gastroenterology and Hepatology, 2014
- Discovery and mechanism of ustekinumabmAbs, 2011
- A Randomized Trial of Ustekinumab, a Human Interleukin-12/23 Monoclonal Antibody, in Patients With Moderate-to-Severe Crohn's DiseaseGastroenterology, 2008